3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
1
Sponsor Class
NIH
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
8
Rectal Neoplasms
4
Anus Neoplasms
4
Urinary Bladder Neoplasms
3
Pancreatic Adenocarcinoma
3
Ovarian Neoplasms
2
Klatskin Tumor
2
Gallbladder Neoplasms
2
Esophageal Neoplasms
2
Colorectal Neoplasms
2
Cholangiocarcinoma
2
Anal Canal Carcinoma
2
Adenocarcinoma Of Esophagus
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7
1
Somatostatinoma
1
Sinonasal undifferentiated carcinoma
1
Paranasal Sinus Neoplasms
1
Neoplasm Metastasis
1
Metastatic Small Intestinal Adenocarcinoma
1
Lung Neoplasms
1
Keratosis, Actinic
1
HIV Infections
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Clinical Stage I Gastric Cancer AJCC v8
1
Clinical Stage 0 Gastric Cancer AJCC v8
1
Interventions
Gemcitabine
20
Fluorouracil
14
Cisplatin
10
Capecitabine
10
Leucovorin
8
durvalumab
6
Oxaliplatin
6
Erlotinib Hydrochloride
4
Sorafenib
3
Radiotherapy
3
trifluridine tipiracil drug combination
2
trametinib
2
regorafenib
2
pembrolizumab
2
olaparib
2
ceralasertib
2
Specimen Handling
2
Radiosurgery
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Irinotecan
2
Filgrastim
2
AZD 6244
2
zimberelimab
1
tremelimumab
1
titanium silicide
1
tislelizumab
1
tegafur-gimeracil-oteracil
1
seribantumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Bile Duct Neoplasms
×
dehydroftorafur
×
Clear all
NCT02042443
2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2
Completed
53 enrolled
13 charts